In order to test the hypothesis that the EGFR pathway is triggered as a compensatory mechanism for c-Met+ HCC survival after c-Met knockdown, we sought to determine which EGFR family members and/or ligands might be upregulated by c-Met inhibition. The gene discussed is MET; the disease is hepatocellular carcinoma.